Pharmaceutical Technology

NOVEMBER 9, 2022

Known by the brand name Roctavian, BioMarin’s haemophilia A therapy valoctocogene roxaparvovec could be fairly priced in the range of $1.95–1.96 BioMarin’s Roctavian has a target PDUFA action date of March 31 next year. million price tag. million, the think tank concluded in its updated evaluation. million ($1.5

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

XTalks

DECEMBER 13, 2023

Related: Roctavian Becomes First Gene Therapy for Severe Hemophilia A to Get FDA Nod Casgevy and Lyfgenia Pricing and Warnings The price tags of both gene therapies are steep, given the complexity of developing gene therapies and as therapies meant to be one-time treatments.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

pharmaphorum

AUGUST 26, 2022

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe. BioMarin has said Roctavian will be available at a ‘net’ price of around €1.5 million spread over five years.

Gene Therapy 109

Gene Therapy Gene Antibody Marketing 109

Pharmaceutical Technology

JANUARY 27, 2023

Other companies like BioMarin have already announced an intention to offer an outcomes-based warranty program for its hemophilia A drug Roctavian (valoctocogene roxaparvovec). In 2022, the number of risk sharing agreements peaked with 144 agreements being made in the pharmaceutical industry.

Manufacturing 130

Manufacturing Drugs Research Analyst FDA Approval 130

XTalks

NOVEMBER 24, 2022

Related: Roctavian, the First Hemophilia A Gene Therapy, Attains EC Approval. While the price tag of Hemgenix is quite steep, CSL Behring told Fierce Pharma that the cost of treating patients with moderate to severe hemophilia to healthcare systems is more than $20 million over their lifetimes.

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52